Paper26789727
Assessment of Minimal Residual Disease in Standard-Risk AML.
Ivey A and 22 others. N Engl J Med, 2016. Cited by 704 papers, by iCite.
Cite this record
ConductScience Library. Assessment of Minimal Residual Disease in Standard-Risk AML. Papers, record 26789727. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26789727
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Mutation | Major topic |
| Nuclear Proteins | Major topic |
| Base Sequence | |
| DNA, Neoplasm | |
| Exome | |
| Gene Expression Profiling | |
| Humans | |
| Molecular Sequence Data | |
| Neoplasm, Residual | |
| Nucleophosmin | |
| Prognosis | |
| Recurrence | |
| Reverse Transcriptase Polymerase Chain Reaction | |
| Risk Factors | |
| Transcriptome |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| RP-PG-0108-10093 | Department of Health | United Kingdom | PubMed | |
| 9948 | Cancer Research UK | United Kingdom | PubMed | |
| G0500392 | Medical Research Council | United Kingdom | PubMed | |
| 15556 | Cancer Research UK | United Kingdom | PubMed | |
| G1000729 | Medical Research Council | United Kingdom | PubMed | |
| WT097143MA | Wellcome Trust | United Kingdom | PubMed | |
| MR/L008963/1 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04689815 | Oral Arsenic Trioxide for NPM1-mutated AML | Background |
Source ClinicalTrials.gov
Comments and corrections6
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 26789634 | Minimal Residual Disease in NPM1-Mutated AML. | https://conductscience.org/library/papers/26789634 | PubMed |
| Comment in | 26856743 | Haematological cancer: MRD assessment - guiding decisions for patients with AML. | https://conductscience.org/library/papers/26856743 | PubMed |
| Comment in | 27509124 | Assessment of Minimal Residual Disease in Standard-Risk AML. | https://conductscience.org/library/papers/27509124 | PubMed |
| Comment in | 27509125 | Assessment of Minimal Residual Disease in Standard-Risk AML. | https://conductscience.org/library/papers/27509125 | PubMed |
| Comment in | 27509126 | Assessment of Minimal Residual Disease in Standard-Risk AML. | https://conductscience.org/library/papers/27509126 | PubMed |
| Comment in | 27509127 | Assessment of Minimal Residual Disease in Standard-Risk AML. | https://conductscience.org/library/papers/27509127 | PubMed |
Cited by459
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 704 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42946711 | Outcomes with fractionated gemtuzumab ozogamicin in molecularly defined favorable-risk acute myeloid leukemia. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/42946711 | PubMed |
| 42938803 | Interferon Therapy in Acute Myeloid Leukemia: Biological Rationale, Clinical Evidence, and Future Directions. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938803 | PubMed |
| 42850349 | Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy. | Leukemia | 2026 | https://conductscience.org/library/papers/42850349 | PubMed |
| 42795012 | Two Decades of NPM1-Mutated Acute Myeloid Leukemia: From Molecular Insights to Clinical Decision-Making. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42795012 | PubMed |
| 42739525 | Indications for Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation in Adults: State of the Art. | J Clin Med | 2026 | https://conductscience.org/library/papers/42739525 | PubMed |
| 42649900 | FLT3-ITD Measurable Residual Disease in Acute Myeloid Leukemia: Implications for FLT3 Inhibitor-Based Therapies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649900 | PubMed |
| 42640163 | Consolidation Therapy Based on Mutation Clearance in Acute Myeloid Leukemia. | NEJM Evid | 2026 | https://conductscience.org/library/papers/42640163 | PubMed |
| 42599754 | FLT3-ITD MRD is here to stay. | Blood Adv | 2026 | https://conductscience.org/library/papers/42599754 | PubMed |
| 42545548 | Analytical validation of a modified wild-type blocker qpcr assay for the sensitive DNA-based detection of NPM1 type A in acute myeloid leukemia. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42545548 | PubMed |
| 42532509 | Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML. | Blood Adv | 2026 | https://conductscience.org/library/papers/42532509 | PubMed |
| 42471330 | Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/42471330 | PubMed |
| 42469476 | Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry. | Leukemia | 2026 | https://conductscience.org/library/papers/42469476 | PubMed |
| 42452347 | Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin. | J Clin Med | 2026 | https://conductscience.org/library/papers/42452347 | PubMed |
| 42439986 | MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia. | Ann Hematol | 2026 | https://conductscience.org/library/papers/42439986 | PubMed |
| 42350077 | When MRD Is Not MRD: A Context-Dependent Interpretation in Clinical Decision-Making. | Eur J Haematol | 2026 | https://conductscience.org/library/papers/42350077 | PubMed |
| 42329370 | [Guideline development for MRD diagnostics in AML as a blueprint for solid tumors]. | Pathologie (Heidelb) | 2026 | https://conductscience.org/library/papers/42329370 | PubMed |
| 42279386 | Advances in Immune Checkpoint Inhibitors for Cancer Treatment. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279386 | PubMed |
| 42249961 | Splicing factor mutations clearance and outcomes in clonal myeloid neoplasms: a referral center experience. | Ann Hematol | 2026 | https://conductscience.org/library/papers/42249961 | PubMed |
| 42230972 | Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations. | Br J Haematol | 2026 | https://conductscience.org/library/papers/42230972 | PubMed |
| 42196346 | Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196346 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| NPM1 | 4869 | PubTator's text mining | https://conductscience.org/library/genes/4869 |
Source NCBI Gene
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| ISRCTN | ISRCTN55675535 |
Source ISRCTN
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- References
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26789727
GET https://conductscience.org/api/papers/v1/26789727/authors?page=2